Diabetes Center and Department of Medicine, University of California, San Francisco, San Francisco, California 94143, USA.
Nat Rev Immunol. 2010 Nov;10(11):797-803. doi: 10.1038/nri2869.
Immune tolerance-inducing therapies reprogramme immune cells to eliminate pathogenic immune responses while preserving protective immunity. The Immune Tolerance Network (ITN), sponsored by the US National Institutes of Health, was established in 1999 to evaluate new tolerance-inducing therapies and carry out mechanistic studies using a unique interactive approach in partnership with industry, academia and foundations. Ten years later, the ITN has carried out approximately 36 clinical trials and tolerance studies examining innovative tolerogenic approaches in the settings of allergy, autoimmune diseases and organ transplantation. ITN investigators have published more than 80 original research papers based on this work. This Timeline article summarizes the progress and challenges of clinical research in the ITN.
免疫耐受诱导疗法可重新编程免疫细胞，消除致病免疫反应，同时保留保护性免疫。免疫耐受网络（ITN）由美国国立卫生研究院资助，成立于 1999 年，旨在评估新的诱导耐受疗法，并通过与工业界、学术界和基金会合作的独特互动方式进行机制研究。十年后，ITN 已经进行了大约 36 项临床试验和耐受研究，检查了过敏、自身免疫性疾病和器官移植环境中的创新耐受方法。ITN 研究人员根据这项工作发表了 80 多篇原创研究论文。本文总结了 ITN 临床研究的进展和挑战。
